Inclusion Criteria:  Patients with multiple sclerosis (MS) with neurogenic detrusor overactivity proven by urodynamics Stable MS with an Expanded Disability Severity Score (EDSS) less than or equal to 6.5 Voluntary micturitions Number of micturitions > 8 per day, with or without episodes of urgency and urgency incontinence Signed informed consent form  Exclusion Criteria:  Pregnancy, breastfeeding Patients requiring self-catheterizations Patients unable or unwilling to learn self-catheterisation Recent (<12 weeks) or current treatment with botulinum toxin for any non-urological indication Recent (≤ 8 weeks) or current treatment with anticholinergic drugs Patients with a positive history or evidence of pelvic / urological abnormality (interstitial cystitis, bladder lithiasis in the 6 months preceding the screening, or any other condition / operation affecting the bladder or prostate)  Any contraindication to Vesicare®:  Hypersensitivity to the active ingredient or to one of the excipients Urinary retention Untreated narrow-angle glaucoma Severe gastrointestinal illness (e.g. toxic megacolon) Myasthenia gravis Severe hepatic failure Hemodialysis Severe renal failure, or liver function disturbances of moderate severity with concomitant treatment with a strong inhibitor of the CYP3A4 isoenzyme, including patients at risk for these diseases.  Any contraindication to BOTOX®:  Known hypersensitivity to the active substance or to one of the excipients Presence of a symptomatic infection at the planned injection site(s) Urinary tract infection at the time of planned treatment Patients who present with acute urinary retention at the time of treatment and who do not regularly use bladder catheterization Patients who do not want and / or cannot, if necessary, perform self-intermittent catheterisation